Elisa Pasqua

Elisa Pasqua

Auto-generated profile, based on publicly available information

Elisa Pasqua

Centre for Cancer Drug Discovery at The Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
NCNicola E. A. Chessum
Nicola E. A. Chessum
SSSwee Y. Sharp
Swee Y. Sharp
JCJohn J. Caldwell
John J. Caldwell
APA. Elisa Pasqua
A. Elisa Pasqua
BWBirgit Wilding
Birgit Wilding
KJKeith Jones
Keith Jones
Demonstrating intracellular protein target engagement is an essential step in the development and progression of new chemical probes and potential small molecule therapeutics. However, this can be particularly challenging for poorly studied and noncatalytic proteins, as robust proximal biomarkers are rarely known. To confirm that our recently discovered chemical probe 1 (CCT251236) binds the putative transcription factor regulator pirin in living cells, we developed a heterobifunctional protein degradation probe. Focusing on linker design and physicochemical properties, we generated a highly active probe 16 (CCT367766) in only three iterations, validating our efficient strategy for degradation probe design against nonvalidated protein targets.

5 April 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
APA. Elisa Pasqua
A. Elisa Pasqua
SSSwee Y. Sharp
Swee Y. Sharp
NCNicola E. A. Chessum
Nicola E. A. Chessum
AHAngela Hayes
Angela Hayes
LPLoredana Pellegrino
Loredana Pellegrino
MCMatthew D. Cheeseman
Matthew D. Cheeseman

9 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JWJonathan Welti
Jonathan Welti
DBDenisa Bogdan
Denisa Bogdan
IFInes Figueiredo
Ines Figueiredo
ICIlsa Coleman
Ilsa Coleman
JJJuan Manuel Jiménez-Vacas
Juan Manuel Jiménez-Vacas
ASAdam Sharp
Adam Sharp
Purpose: Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced prostate cancer, but treatment resistance is inevitable and includes reactivation of AR signaling. Novel therapeutic approaches targeting these mechanisms to block tumor growth is an urgent unmet clinical need. One attractive strategy is to target heat shock proteins (HSP) critical to AR functional activity. Experimental Design: We first did transcriptome analysis on multiple castration-resistant prostate cancer (CRPC) cohorts to correlate the association between the Gene Ontology cellular response to heat gene expression signature and overall survival. Next, we analyzed the impact of targeting the heat shock factor 1 (HSF1) pathway, with an inhibitor in clinical development, namely, NXP800 (formerly CCT361814), in models of treatment-resistant prostate cancer. Finally, we confirmed our mechanistic and phenotypic findings using an NXP800-resistant model and an in vivo model of CRPC. Results: We report that in multiple CRPC transcriptome cohorts, the Gene Ontology cellular response to heat gene expression signature associates with AR signaling and worse clinical outcome. We demonstrate the effects of targeting the HSF1 pathway, central to cellular stress, with an inhibitor in clinical development, namely, NXP800, in prostate cancer. Targeting the HSF1 pathway with the inhibitor NXP800 decreases HSP72 expression, activates the unfolded protein response, and inhibits AR- and E2F-mediated activity, inhibiting the growth of treatment-resistant prostate cancer models. Conclusions: Overall, NXP800 has antitumor activity against treatment-resistant prostate cancer models, including molecular subtypes with limited treatment options, supporting its consideration for prostate cancer–specific clinical development.

1 June 2021 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
BWBirgit Wilding
Birgit Wilding
APA. Elisa Pasqua
A. Elisa Pasqua
NCNicola E. A. Chessum
Nicola E. A. Chessum
OPOlivier A. Pierrat
Olivier A. Pierrat
THTamas Hahner
Tamas Hahner
MCMatthew D. Cheeseman
Matthew D. Cheeseman
ERAP1 is a zinc-dependent M1-aminopeptidase that trims lipophilic amino acids from the N-terminus of peptides. Owing to its importance in the processing of antigens and regulation of the adaptive immune response, dysregulation of the highly polymorphic ERAP1 has been implicated in autoimmune disease and cancer. To test this hypothesis and establish the role of ERAP1 in these disease areas, high affinity, cell permeable and selective chemical probes are essential. DG013A 1, is a phosphinic acid tripeptide mimetic inhibitor with reported low nanomolar affinity for ERAP1. However, this chemotype is a privileged structure for binding to various metal-dependent peptidases and contains a highly charged phosphinic acid moiety, so it was unclear whether it would display the high selectivity and passive permeability required for a chemical probe. Therefore, we designed a new stereoselective route to synthesize a library of DG013A 1 analogues to determine the suitability of this compound as a cellular chemical probe to validate ERAP1 as a drug discovery target.

16 September 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DPDaniele Pala
Daniele Pala
DCDavid Clark
David Clark
CEChristine Edwards
Christine Edwards
EPElisa Pasqua
Elisa Pasqua
LTLaura Tigli
Laura Tigli
AAAlessandro Accetta
Alessandro Accetta
We report the characterization of potent and selective ROCK inhibitors identified through a core-hopping strategy. A virtual screening workflow, combining ligand- and structure-based methods, was applied on a known series of ROCK inhibitors bearing an acetamido-thiazole scaffold. The most promising replacement of the central core was represented by a benzoazepinone ring, which was selected as a starting point for a subsequent chemical exploration. The overall design approach exploited previous SARs available for congeneric series and crystallographic information to optimize the hinge-binding group as well as the terminal aromatic moiety interacting with the glycine-rich loop. The introduction of elongated and flexible charged groups led to compound 15, which exhibited sub-nanomolar potencies in biochemical and cellular assays, as well as a remarkable selectivity over PKA. HDX studies not only supported the postulated binding mode of compound 15 but also confirmed the crucial role of specific ROCK peptide segments in driving ligand selectivity.

17 March 2025
Verified
Other
Open access
JWJonathan Welti
Jonathan Welti
DBDenisa Bogdan
Denisa Bogdan
IFInes Figueiredo
Ines Figueiredo
ICIlsa Coleman
Ilsa Coleman
JJJuan Manuel Jiménez-Vacas
Juan Manuel Jiménez-Vacas
ASAdam Sharp
Adam Sharp
Supplementary figure 9: NXP800 demonstrates tolerability in a castration-resistant VCaP PCa cell line-derived mouse xenograft